MX364207B - Inhibidores de agrecanasa. - Google Patents

Inhibidores de agrecanasa.

Info

Publication number
MX364207B
MX364207B MX2015005297A MX2015005297A MX364207B MX 364207 B MX364207 B MX 364207B MX 2015005297 A MX2015005297 A MX 2015005297A MX 2015005297 A MX2015005297 A MX 2015005297A MX 364207 B MX364207 B MX 364207B
Authority
MX
Mexico
Prior art keywords
aggrecanase inhibitors
aggrecanase
inhibitors
cyclopropyl
intermediates
Prior art date
Application number
MX2015005297A
Other languages
English (en)
Other versions
MX2015005297A (es
Inventor
Barrett Durham Timothy
Marimuthu Jothirajah
Robert Wiley Michael
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Publication of MX2015005297A publication Critical patent/MX2015005297A/es
Publication of MX364207B publication Critical patent/MX364207B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos que tienen la fórmula: en donde R1 se selecciona de metilo, etilo, propilo, ciclopropilo, y dimetilo, o una sal del mismo farmacéuticamente aceptable, junto con métodos y productos intermediarios para su preparación, y usos de los mismos. (ver Fórmula).
MX2015005297A 2012-10-26 2013-10-18 Inhibidores de agrecanasa. MX364207B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261718965P 2012-10-26 2012-10-26
PCT/US2013/065591 WO2014066151A1 (en) 2012-10-26 2013-10-18 Aggrecanase inhibitors

Publications (2)

Publication Number Publication Date
MX2015005297A MX2015005297A (es) 2015-07-17
MX364207B true MX364207B (es) 2019-04-16

Family

ID=49515523

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005297A MX364207B (es) 2012-10-26 2013-10-18 Inhibidores de agrecanasa.

Country Status (20)

Country Link
US (1) US9206139B2 (es)
EP (1) EP2912021B1 (es)
JP (1) JP6251279B2 (es)
KR (1) KR101689983B1 (es)
CN (1) CN104755464B (es)
AR (1) AR092971A1 (es)
AU (1) AU2013334989B2 (es)
BR (1) BR112015009032B1 (es)
CA (1) CA2886526C (es)
DK (1) DK2912021T3 (es)
EA (1) EA026037B1 (es)
ES (1) ES2645970T3 (es)
HK (1) HK1211927A1 (es)
HU (1) HUE034616T2 (es)
MX (1) MX364207B (es)
NZ (1) NZ706772A (es)
PL (1) PL2912021T3 (es)
PT (1) PT2912021T (es)
TW (1) TWI620738B (es)
WO (1) WO2014066151A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ730634A (en) 2014-10-16 2023-02-24 Monsanto Technology Llc Lepidopteran-active cry1da1 amino acid sequence variant proteins
JO3501B1 (ar) 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
GB201610055D0 (en) 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201610056D0 (en) 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
WO2021011723A1 (en) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Anti-osteoarthritis hydantoin compounds and related compositions and methods
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
WO2021214637A1 (en) * 2020-04-20 2021-10-28 St. Jude Children's Research Hospital Composition and methods for treating respiratory diseases
WO2022007866A1 (zh) * 2020-07-09 2022-01-13 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096426A1 (en) * 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
MX2007016270A (es) * 2005-06-27 2008-03-05 Amgen Inc Compuestos aril nitrilo anti-inflamatorios.
GT200600306A (es) * 2005-07-11 2007-03-29 Inhibidores de glutamato agrecanasa
AR059036A1 (es) * 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
TWI620738B (zh) 2018-04-11
BR112015009032B1 (pt) 2022-06-28
PT2912021T (pt) 2017-11-14
NZ706772A (en) 2018-05-25
CN104755464B (zh) 2017-03-29
JP2015535248A (ja) 2015-12-10
US9206139B2 (en) 2015-12-08
ES2645970T3 (es) 2017-12-11
AR092971A1 (es) 2015-05-06
TW201427955A (zh) 2014-07-16
EP2912021B1 (en) 2017-08-16
WO2014066151A1 (en) 2014-05-01
HK1211927A1 (en) 2016-06-03
MX2015005297A (es) 2015-07-17
US20150218107A1 (en) 2015-08-06
BR112015009032A2 (pt) 2017-07-04
JP6251279B2 (ja) 2017-12-20
HUE034616T2 (en) 2018-02-28
CN104755464A (zh) 2015-07-01
EA026037B1 (ru) 2017-02-28
DK2912021T3 (en) 2017-10-02
CA2886526C (en) 2018-03-27
AU2013334989A1 (en) 2015-04-23
EP2912021A1 (en) 2015-09-02
KR20150058480A (ko) 2015-05-28
AU2013334989B2 (en) 2016-02-18
CA2886526A1 (en) 2014-05-01
KR101689983B1 (ko) 2016-12-26
EA201590621A1 (ru) 2015-07-30
PL2912021T3 (pl) 2018-01-31

Similar Documents

Publication Publication Date Title
MX364207B (es) Inhibidores de agrecanasa.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12016500169A1 (en) Polymorph of syk inhibitors
MX2015012629A (es) Compuestos de imidazo piridina.
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
IN2015DN00598A (es)
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
JO3318B1 (ar) مثبطات bace
PH12015500009B1 (en) Phenoxyethyl piperidine compounds
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
IN2014DN07996A (es)
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
IN2014DN06192A (es)
RS65412B1 (sr) Intermedijeri za pripremu c-terminalnog inhibitora hsp90
ZA201301799B (en) Process for the preparation of pan-cdk inhibitors of the formula (i),and intermediates of the preparation
MX337610B (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
IN2013MU02010A (es)
IN2014MU00070A (es)
IN2013MU01524A (es)

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ELANCO US INC.

FG Grant or registration